EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review

Deep Dutta, Ritin Mohindra, Manoj Kumar, Mainak Banerjee, Meha Sharma, Satinath Mukhopadhyay

The Indian Journal of Medical Research · 31.05.2025 · 161 · 363-374

DOI: 10.25259/ijmr_1990_2024 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Indian Journal of Medical Research, online erschienen am 31.05.2025. Verfasst von Deep Dutta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Centre for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, New Delhi, India. Hauptthemen laut MEDLINE: Gabapentin, Pregabalin, Stroke, Myocardial Infarction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & objectives A few propensity-score-matched cohort studies have suggested increased cardiovascular events with gabapentinoids (gabapentin/pregabalin). This systematic review analysed the cardiovascular safety of gabapentin and pregabalin in clinical practice.

Methods

Databases were searched for articles examining the occurrence of cardiovascular events with gabapentin and pregabalin in different clinical conditions. The primary outcome was to look at the occurrence of myocardial infarction (MI) and stroke. Secondary outcomes were to look at the occurrence of deep venous thrombosis (DVT), peripheral artery disease (PAD), pulmonary thrombo-embolism (PTE), heart failure (HF) and atrial fibrillation (AF).

Results

Data from five cohort studies (10,85,488 patients) were analysed. Gabapentin use was associated with increased risk of MI after one year of [Hazard ratio (HR) 1.31(1.14,1.52); I 2 =0%; P= 0.0002] use. Gabapentinoids were associated with increased risk of stroke after five years of use [HR 1.44 (1.04, 2.01); I 2 =86%; P= 0.03]. Heart failure was not increased with the use of gabapentinoids. Their chronic use was associated with increased risk of PVD after one year [HR 1.41(1.18, 1.67); P= 0.0001] and five years [HR 1.58 (1.16, 2.15); I 2 =83%; P= 0.003] use. Gabapentinoid use was associated with increased risk of DVT after three months [HR 1.37(1.21, 1.55); P< 0.00001], one-year [HR 1.42 (1.15, 1.74); P= 0.0009], and five years [HR 1.78 (1.31,2.40); I 2 =71%; P= 0.0002] use. Their use was associated with increased risk of pulmonary embolism after three months [HR 1.27 (1.09, 1.46); P= 0.002], one-year [HR 1.23 (1.01, 1.40); P= 0.04], and five years of [HR 1.86 (1.64, 2.09); I 2 =0%; P< 0.0001] use. Interpretation & conclusions The use of gabapentinoids was associated with increased risks of thrombotic events as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GabapentinPregabalinStrokeMyocardial InfarctionCardiovascular DiseasesHumansPulmonary EmbolismVenous ThrombosisAtrial FibrillationHeart FailurePeripheral Arterial Disease

Stichwörter der Autor:innen

Cardiovasculargabapentingabapentinoidsmetanalysispregabalin

Substanzen

GabapentinPregabalin

Autor:innen und Institutionen

  • Department of Endocrinology, Centre for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, New Delhi, India.
  • Department of Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Endocrinology, Maharishi Markandeshwar Institute of Medical Sciences, Ambala, Haryana, India.
  • Department of Endocrinology, Ramakrishna Mission Seva Pratisthan Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India.
  • Department of Rheumatology, Centre for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, New Delhi, India.
  • Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India.

Zitieren

APA

Dutta, D., Mohindra, R., Kumar, M., Banerjee, M., Sharma, M., & Mukhopadhyay, S. (2025). Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review. The Indian Journal of Medical Research, 161, 363-374. https://doi.org/10.25259/ijmr_1990_2024

Vancouver

Dutta D, Mohindra R, Kumar M, Banerjee M, Sharma M, Mukhopadhyay S. Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review. The Indian Journal of Medical Research. 2025;161:363-374. doi:10.25259/ijmr_1990_2024

BibTeX
@article{Dutta2025,
  author = {Dutta, Deep and Mohindra, Ritin and Kumar, Manoj and Banerjee, Mainak and Sharma, Meha and Mukhopadhyay, Satinath},
  title = {Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review},
  journal = {The Indian Journal of Medical Research},
  year = {2025},
  volume = {161},
  pages = {363--374},
  doi = {10.25259/ijmr_1990_2024}
}
Kostenlos starten →